Pfizer reported $3.2 billion in Q2 sales from new and acquired products, an 18% increase year-over-year, nearing a $13 billion annual run-rate. The company has cut $7.2 billion in costs and beaten earnings estimates for 10 consecutive quarters. However, COVID-related revenue is expected to drop to $4 billion by 2026, reducing a key earnings source. Analysts predict earnings per share will decline through 2029 due to patent expirations, with a sharp 15.33% drop expected in 2028. Pfizer currently trades at about 9.5 times forward earnings with a 6% yield, but sustained growth is needed to improve its valuation.
Pfizer's ongoing earnings challenges highlight the importance of its current market performance. On Pluang, Pfizer shares trade at USD 28.39 with a slight 0.04% decrease as of Oct 13, 2026, 20:42 WIB. The stock offers a 6.06% dividend yield and shows balanced investor interest with 56% buy orders and 44% sell orders, reflecting cautious optimism among traders.
Pfizer's dividend yield has risen above 6%, notably higher than peers, due to a share price decline despite steady dividends. While the company maintains a strong earnings buffer and CEO Albert Bourla has assured the dividend will hold, free cash flo...
Moderna's stock rose 5% following its addition to the NASDAQ 100, driven by automatic fund buying linked to the index inclusion. This marks a shift from its COVID-19 vaccine identity to a growth biotech with a promising oncology pipeline, highlighted...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Four well-known companies—Pfizer, UPS, Kraft Heinz, and Ford—offer dividend yields above 5%, but their earnings, cash flow, and debt levels raise doubts about the sustainability of these payouts. Pfizer and UPS pay dividends exceeding their GAAP earn...
Pfizer expects its stronger non-COVID business to more than offset lower revenue from COVID-related products, though full-year revenue guidance still indicates a decline. The company plans to achieve $2.7 billion in cost savings through 2029, which c...
